DMAC vs. SLS, ALLK, PMVP, BTAI, PRPH, ABEO, MIST, GNLX, BYSI, and ORMP
Should you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include SELLAS Life Sciences Group (SLS), Allakos (ALLK), PMV Pharmaceuticals (PMVP), BioXcel Therapeutics (BTAI), ProPhase Labs (PRPH), Abeona Therapeutics (ABEO), Milestone Pharmaceuticals (MIST), Genelux (GNLX), BeyondSpring (BYSI), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical preparations" industry.
DiaMedica Therapeutics (NASDAQ:DMAC) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, community ranking, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.
DiaMedica Therapeutics has higher earnings, but lower revenue than SELLAS Life Sciences Group. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, DiaMedica Therapeutics had 5 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 5 mentions for DiaMedica Therapeutics and 0 mentions for SELLAS Life Sciences Group. DiaMedica Therapeutics' average media sentiment score of 0.73 beat SELLAS Life Sciences Group's score of 0.00 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.
DiaMedica Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500.
DiaMedica Therapeutics' return on equity of -40.07% beat SELLAS Life Sciences Group's return on equity.
10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 7.2% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 1.6% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
DiaMedica Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 171.32%. SELLAS Life Sciences Group has a consensus price target of $3.00, indicating a potential upside of 105.48%. Given DiaMedica Therapeutics' higher possible upside, equities research analysts clearly believe DiaMedica Therapeutics is more favorable than SELLAS Life Sciences Group.
DiaMedica Therapeutics received 80 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 62.07% of users gave DiaMedica Therapeutics an outperform vote while only 58.82% of users gave SELLAS Life Sciences Group an outperform vote.
Summary
DiaMedica Therapeutics beats SELLAS Life Sciences Group on 11 of the 15 factors compared between the two stocks.
Get DiaMedica Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DiaMedica Therapeutics Competitors List
Related Companies and Tools
